Replies to post #1364 on JanOne Inc (JAN)

[TheFinalCD]

Dr. Soin's appearance extends JanOne's busy period of recent announcements. On August 29, the company revealed it had received a US Patent for use of its novel formulation of low-dose naltrexone (Jan123) to treat chronic pain. Tony Isaac, JanOne's CEO, said that the new patent's broad language—covering methods of using JanOne's formulation of low-dose naltrexone to treat chronic pain—"provides robust and broad coverage and protection, and lengthens the timeline for sales significantly."

Also in August, Dr. Soin's team won a prestigious "Best Abstract" award for reporting that JanOne's treatment for diabetic neuropathy showed both effectiveness against pain and potential to improve nerve function. The abstract, which was presented to the influential Ohio Society of Interventional Pain Physicians (OHSIPP), analyzed prior data on Jan101's randomized double blind placebo-controlled trial in diabetic neuropathy patients.

More recently–in early September—Dr. Soin had another opportunity to engage investors focused on innovative growth companies. He presented to H.C. Wainwright's 25th Annual Global Investment Conference.

CEO Isaac commented on the company's recent visibility: "We're being invited to tell our story about new approaches to treating pain and underlying causes of pain," he said. "Thousands continue to suffer from opioid-related addiction and deaths. Our mission—to find non-addictive alternatives—has never been more relevant or more urgent."